Although there are several real-world pieces of data which outline the difference in clinical efficacy between first- and second-generation EGFR-TKIs in advanced EGFR-mutant NSCLC patients, the results were inconsistent. This evidence concerns the gene EGFR and non-small cell lung carcinoma.